Key questions about the checkpoint blockade-are microRNAs an answer?

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Immune-checkpoint blockade has revolutionized late-stage cancer therapy, with multiple FDA-approved inhibitors in clinical trials.
• Despite expanded indications, identifying patients who benefit from immune checkpoint inhibitors remains a challenge.
• MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally.

Purpose of the Study:

• To review microRNAs that control immune checkpoint expression.
• To discuss current limitations in immune checkpoint therapy, including therapeutic indication, response evaluation, adverse events, and lack of response.
• To propose microRNAs as potential solutions to overcome these therapeutic challenges.

Main Methods:

• Literature review focusing on microRNAs involved in immune checkpoint regulation.
• Analysis of microRNA networks targeting multiple checkpoint molecules.
• Discussion of clinical challenges in immune checkpoint therapy and potential miRNA-based interventions.

Main Results:

• MicroRNAs can target multiple immune checkpoint molecules, potentially mimicking combined blockade therapy.
• Specific microRNAs are identified as regulators of key immune checkpoint receptors.
• MicroRNAs offer a potential mechanism to address limitations in current immune checkpoint therapy.

Conclusions:

• MicroRNAs play a crucial role in regulating immune checkpoints.
• MicroRNAs hold promise for overcoming challenges in immune checkpoint therapy, including patient selection and managing adverse events.
• MicroRNAs may serve as future therapeutic partners to enhance the efficacy of immune checkpoint blockade in cancer treatment.